Mira PharmaceuticalsMIRA -0.26%13 Quick Ratio is 81.98 as of Mar. 2026, which is 1338% above its 10-year median of 5.70. GuruFocus rates MIRA with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 996 Drug Manufacturers companies, Mira Pharmaceuticals ranks better than 99.7% on this metric.
Mira Pharmaceuticals has a quick ratio of 81.98. It generally indicates good short-term financial strength.
The historical rank and industry rank for Mira Pharmaceuticals's Quick Ratio or its related term are showing as below:
MIRA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.12 Med: 5.7 Max: 90.45
Current: 81.98
During the past 5 years, Mira Pharmaceuticals's highest Quick Ratio was 90.45. The lowest was 0.12. And the median was 5.70.
MIRA's Quick Ratio is ranked better than 99.7% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs MIRA: 81.98
Mira Pharmaceuticals (NAS:MIRA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Mira Pharmaceuticals Quick Ratio Related Terms
Mira Pharmaceuticals Quick Ratio Historical Data
* Premium members only.
The historical data trend for Mira Pharmaceuticals's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mira Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Mira Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Mira Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mira Pharmaceuticals (MIRA) has a Quick Ratio of 81.98 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Mira Pharmaceuticals and its competitors. This is 1338% above median its historical median of 5.70. Over the past decade, Mira Pharmaceuticals' Quick Ratio has ranged from 0.12 to 90.45. According to the industry distribution chart, Mira Pharmaceuticals ranks #3 out of 996 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Mira Pharmaceuticals' Quick Ratio too high?
Mira Pharmaceuticals' current Quick Ratio of 81.98 is 1338% above median its 10-year median of 5.70. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 90.45. The Drug Manufacturers industry median Quick Ratio is 1.45. Mira Pharmaceuticals' value of 81.98 is 5553.8% above this industry median. Based on the distribution chart, Mira Pharmaceuticals ranks #3 out of 996 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mira Pharmaceuticals has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Mira Pharmaceuticals' Quick Ratio compare to NSRX and SCLX?
According to the Drug Manufacturers industry distribution chart, Mira Pharmaceuticals ranks #3 out of 996 companies for Quick Ratio. This places Mira Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Mira Pharmaceuticals' value of 81.98 is 5553.8% above this benchmark. Historically, Mira Pharmaceuticals' own Quick Ratio has ranged from 0.12 to 90.45 over the past decade. While the company's 10-year median is 5.70 vs. the industry median of 1.45, Mira Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mira Pharmaceuticals's current Quick Ratio of 81.98 is 5553.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Mira Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mira Pharmaceuticals's current Quick Ratio is 81.98, which is 1338% above median its own 10-year median of 5.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mira Pharmaceuticals stock overvalued right now?
Mira Pharmaceuticals (MIRA) has a current Quick Ratio of 81.98. The current Quick Ratio is 81.98, which is 1338% above median its 10-year median of 5.70 and 5553.8% above the Drug Manufacturers industry median of 1.45. Mira Pharmaceuticals' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Mira Pharmaceuticals (MIRA), the current Quick Ratio is 81.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
13GF Score
Get the complete analysis for MIRA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIRA has been successfully added to your 
